Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cubist Pharmaceuticals Announces Senior Executive Appointments

Published: Tuesday, July 03, 2012
Last Updated: Tuesday, July 03, 2012
Bookmark and Share
Robert J. Perez, currently Executive Vice President and Chief Operating Officer (COO), has been named President and COO.

Michael Tomsicek, currently Vice President of Corporate Finance, has been named Senior Vice President and Deputy Chief Financial Officer. In addition, Thomas Rollins has been appointed Senior Vice President of Program and Portfolio Management.

"As we recently articulated in our Building Blocks of Growth strategic goals, attracting, retaining and developing top talent are critical to growing and expanding our business on a global basis, and I am delighted today to announce these senior appointments," said Michael Bonney, Chief Executive Officer.

"Rob and Mike are exceptional leaders who have made significant contributions to our recent operational and financial success, and we're pleased to have them take on added responsibilities. We're also delighted that Tom will join our senior Cubist leadership team, adding strengths across all phases of our product development process."

In Mr. Perez's role as President and COO, he will oversee all global commercial, manufacturing, business development, and information technology functions. In this capacity, he will have responsibility for overseeing Cubist's international business expansion. Mr. Perez has been EVP and COO since 2007. He joined Cubist in 2003 as Senior Vice President of Cubist's sales and marketing team and then served as SVP of Commercial Operations from 2004 to 2007. Prior to joining Cubist, he spent eight years at Biogen Idec, where he most recently served as Vice President of the company's CNS Business Unit. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals, including serving as Regional Business Director.

In Mr. Tomsicek's new role as SVP and Deputy CFO, he will oversee all financial planning and analysis, technical accounting, controllership, treasury, tax, commercial financial services, and strategic sourcing activities, reporting to David McGirr, Chief Financial Officer. Mr. Tomsicek joined Cubist in 2010. Prior to Cubist, he spent eight years at General Electric Healthcare, initially as global operations Finance Manager for its Monitoring business, and then as CFO of its diagnostic ultrasound business and CFO of its global ultrasound product group. Previously, Mr. Tomsicek served in a variety of financial and channel management roles at Motorola.

Mr. Rollins joins Cubist from Sunovion Pharmaceuticals, Inc., a subsidiary of Dainippon Sumitomo Pharmaceuticals Inc., where he has been SVP of Program Management and R&D Planning since 2009. He spent 15 years at Sepracor Inc. most notably serving as Vice President of Development Operations from 2001-2005 and Senior Vice President of Product Development from 2005-2009. Prior to Sepracor, he held numerous senior research and project positions at Merck Research Laboratories.

As SVP of Program and Portfolio Management at Cubist, Mr. Rollins will be responsible for maximizing the value of Cubist products and product candidates on a global basis. He will report to Steven Gilman, Cubist's Executive Vice President, Research & Development and Chief Scientific Officer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!